Target intelligence / Profile preview

RNA, U6 small nuclear 1326, pseudogene (RNU6-1326P)

Target: RNU6-1326P
Molecular classification: Other (Processed pseudogene; Small nuclear RNA pseudogene)

Overview

RNU6-1326P (RNA, U6 small nuclear 1326, pseudogene) is a human processed pseudogene derived from the U6 small nuclear RNA gene family[1][3][5][7]. Small nuclear RNAs like U6 normally participate in the spliceosomal removal of introns from pre-mRNA, but processed pseudogenes such as RNU6-1326P are inactive genetic remnants generated by retrotransposition mechanisms that lack regulatory or coding function[2][3]. They do not encode proteins, do not incorporate into the spliceosome, and typically have no role in normal cell biology or disease[2][3][4]. While a minority of pseudogenes can act as regulatory RNAs (e.g., ceRNAs) or impact gene regulation in disease, there is no evidence supporting such activity for RNU6-1326P[2][3][4]. The locus is annotated in genome databases but is neither a therapeutic nor diagnostic target and lacks reported functional or clinical relevance[3][5][7].

Other names: RNU6-1326PRNA, U6 Small Nuclear 1326, Pseudogene

Mechanism of action

None. There is no mechanism of action relevant to drugs or therapy for this pseudogene

Biological functions

Other (no direct biological function; however, pseudogenes may occasionally impact transcriptional regulation or genome architecture in rare cases through mechanisms such as ceRNA activity, antisense RNA, or via retrotransposition impacts but there is *no evidence* for a defined function for RNU6-1326P specifically)

Disease associations

Other (no established disease associations or roles; no direct clinical relevance reported for RNU6-1326P)

Beyond the preview

Go deeper on RNA, U6 small nuclear 1326, pseudogene (RNU6-1326P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 1326, pseudogene (RNU6-1326P).

Explore the full profile